All In Biotech

Drug Trial Radar · NCT05989711

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)

Last checked: Nov 19, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 212 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

212

Actual

Start

Jul 27, 2023

Primary completion

Nov 25, 2025

Study completion Nov 25, 2025

Sponsor

Lead sponsor
Altimmune, Inc.Industry
Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.

Conditions

  • Non-Alcoholic Steatohepatitis (NASH)

Interventions

  • PemvidutideDrug

    Administered once weekly by subcutaneous injection

  • PlaceboDrug

    Administered once weekly by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosisTime frame: 24 weeks
  2. Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis)Time frame: 24 weeks
  3. Incidence of Treatment Emergent Adverse EventsTime frame: 52 weeks

Locations

40 sites in 3 countries. Site status is shown where the registry gives one.

  • Altimmune Clinical Study Site

    Chandler, Arizona

  • Altimmune Clinical Study Site

    Peoria, Arizona

  • Altimmune Clinical Study Site

    Tucson, Arizona

  • Altimmune Clinial Study Site

    Tucson, Arizona

  • Altimmune Clinical Study Site

    North Hollywood, California

  • Altimmune Clinical Study Site

    Panorama City, California

  • Altimmune Clinical Study Site

    Englewood, Colorado

  • Altimmune Clinical Study Site

    Bradenton, Florida

  • Altimmune Clinical Study Site

    Fort Myers, Florida

  • Altimmune Clinical Study Site

    Hialeah Gardens, Florida

  • Altimmune Clinical Study Site

    Miami Lakes, Florida

  • Altimmune Clinical Study Site

    Port Orange, Florida

  • Altimmune Clinical Study Site

    Sarasota, Florida

  • Altimmune Clinical Study Site

    West Palm Beach, Florida

  • Altimmune Clinical Study Site

    Dalton, Georgia

  • Altimmune Clinical Study Site

    Marietta, Georgia

  • Altimmune Clinical Study Site

    Bastrop, Louisiana

  • Altimmune Clinical Study Site

    Shreveport, Louisiana

  • Altimmune Clinical Study Site

    Clarksville, Tennessee

  • Altimmune Clinical Study Site

    Germantown, Tennessee

  • Altimmune Clinical Study Site

    Austin, Texas

  • Altimmune Clinical Study Site

    Bellaire, Texas

  • Altimmune Clinical Study Site

    Edinburg, Texas

  • Altimmune Clinical Study Site

    Edinburg, Texas

  • Altimmune Clinical Study Site

    Georgetown, Texas

  • Altimmune Clinical Study Site

    Houston, Texas

  • Altimmune Clinical Study Site

    San Antonio, Texas

  • Altimmune Clinical Study Site

    San Antonio, Texas

  • Altimmune Clinical Study Site

    West Jordan, Utah

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Princess Alexandra Hospital/ Translational Research Institute

    Woolloongabba, Queensland, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • St. Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

  • Box Hill Hospital

    Box Hill, Victory, Australia

  • Monash Hospital

    Clayton, Victory, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • Altimmune Clinical Study Site

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.